

1 **Randomized Phase 2 Trial of Lirilumab**
2 **as maintenance Treatment in Acute Myeloid Leukemia:**
3 **Results of the EFFIKIR Trial**

4
5 N.Vey^{1*}, AS.Chretien^{1*}, PY.Dumas², C.Recher³, L.Gastaud⁴, B.Lioure⁵, CE.Bulabois⁶,
6 C.Pautas⁷, JP.Marolleau⁸, S.Lepretre⁹, E.Raffoux¹⁰, X.Thomas¹¹, Y.Hichri¹², C.Bonmati¹³,
7 B.Quesnel¹⁴, P.Rousselot¹⁵, E.Jourdan¹⁶, JV.Malfuson¹⁷, G.Guillerm¹⁸, JH.Bourhis¹⁹,
8 M.Ojeda-Uribe²⁰, M.Hunault²¹, A.Ben Amara¹, MS.Rouvière¹, N.Boucherit¹, P.André²²,
9 C.Preudhomme¹⁴, N.Dulphy¹⁰, A.Toubert¹⁰, N. Ifrah²¹, D.Olive^{1*}, and H.Dombret^{10*}

10

11 ¹Institut Paoli-Calmettes, Marseille, France; ² CHU Bordeaux, Service d'Hématologie Clinique et de Thérapie
12 Cellulaire, F-33000, Bordeaux, France, ³CHU Toulouse, Institut Universitaire du Cancer de Toulouse
13 Oncopole, France, ⁴Centre Antoine Lacassagne, Nice, France, ⁵CHU, Institut de CANcérologie de Strasbourg
14 Europe, ICANS, France, ⁶CHU de Grenoble, France, ⁷Hopital Henri Mondor, Créteil, France, ⁸CHU Amiens,
15 France, ⁹Centre Henri Becquerel, Rouen, France ¹⁰Hôpital Saint Louis, Paris, France; ¹¹CHU Lyon Sud,
16 France, ¹²CHU Montpellier, France, ¹³CHU Nancy, France, ¹⁴CHRU Lille, France, ¹⁵CH de Versailles, France,
17 ¹⁶CHU de Nîmes, France, ¹⁷Hôpital Militaire Percy, Clamart, France, ¹⁸CHU de Brest, France, ¹⁹Institut
18 Gustave Roussy, Villejuif, France, ²⁰CH Mulhouse, France, ²¹CHU Angers, France, ²²Inmate Pharma, Marseille,
19 France.

20

21 * Equally contributed to this work.

22

23

24 Correspondence and requests for materials should be addressed to Norbert Vey and Anne-Sophie Chretien.

25

26 Text word count: 3957

27 Abstract word count: 249

28 Number of figures: 5

29 Number of tables: 2

30 Numbers of supplementary figures: 4

31 Numbers of supplementary tables: 1

32 Number of references: 39

33

34 Short title: Lirilumab in AML: EFFIKIR trial

35 **KEY POINTS**

- 36 • Prolonged full KIR blockade leads to potentially deleterious effects on NK cells, CD8⁺
37 T cells and $v\delta 2^+$ $\gamma\delta$ T cells
38 • Combined inhibitory effects of KIR blockade may have resulted in the impairment of
39 immunosurveillance associated with high rate of relapse

40

41

42

43

44

45

46

47 **ABSTRACT**

48 Lirilumab is a fully human monoclonal antibody designed to block killer inhibitory receptors
49 (KIR), which are major immune checkpoints involved in the regulation of NK cell-mediated
50 killing of HLA-I-expressing tumors. EFFIKIR is a multicenter randomized double-blind 3-
51 arm placebo-controlled phase II trial with lirilumab as single-agent as maintenance therapy of
52 elderly patients with AML in first complete remission (NCT01687387). Two dose schedules
53 led to either continuous or intermittent KIR occupancy. 153 patients were randomized and
54 152 patients were treated after 3+7 induction therapy. The median follow-up was 36.6
55 months. Lirilumab was well tolerated, with no significant hematological toxicity. The median
56 LFS were 17.6, 6.7 and 13.9 months in the 0.1mg/kg arm, 1mg/kg arm and placebo arm,
57 respectively. An excess in early relapse led to early termination of treatment in the 1mg/kg
58 arm. Extensive analysis of immune cell fate following KIR blockade evidenced a decrease of
59 KIR⁺ NK cell absolute counts following KIR blockade, associated with a decrease of Bcl-2.
60 Lirilumab also bound antigen-experienced CD8⁺ T cells, and induced a transient decrease of
61 CD69 expression. Besides, lirilumab bound $\nu\delta^+$ $\gamma\delta$ T cells with a high cytotoxic potential,
62 and induced a decrease of DNAM-1 and Bcl-2, the latter being associated with a decrease of
63 KIR⁺ $\gamma\delta$ T cell, and with a drastic reduction of time to relapse. Overall, the potentially
64 deleterious effects on immune effectors may have resulted in the impairment of immune
65 surveillance associated with an unexpected high rate of early relapse in the group of patients
66 exposed to prolonged full KIR blockade.

67 INTRODUCTION

68 Killer cell Immunoglobulin-like Receptors (KIRs) are a class of major immune checkpoints
69 that negatively regulate Natural Killer (NK) cell anti-tumor activity.^{1,2} Inhibitory KIR,
70 KIR2DL and KIR3DL, display extracellular immunoglobulin-like domains conferring
71 specificity for HLA-C or HLA-A/B allotypes, respectively. Blockade of inhibitory NK
72 receptors has therefore the unique potential to enhance tumor cell killing without affecting
73 healthy tissues. NK cells are cytotoxic against malignant cells, including Acute Myeloid
74 Leukemia (AML)^{1,3}, and AML-induced NK cell alterations are associated with a poor
75 prognosis.^{4,5} KIR blockade by IPH2101, an anti-KIR monoclonal antibody, was found to be
76 generally safe and displayed signals of activity in hematologic malignancies.⁶ Lirilumab
77 (IPH2102/BMS-986015/BMS-986015-01) is a fully human IgG4 monoclonal antibody that
78 binds specifically and with high affinity to the main human inhibitory KIR, KIR2DL1 and
79 KIR2DL2/3. Lirilumab binding blocks the interaction of KIR2DL with HLA-C allotypes,
80 prevents inhibitory signals, and fosters activation NK cell activation. In a phase I study of
81 lirilumab in patients with hematological malignancies and solid tumors, we have shown that
82 as for IPH2101, lirilumab was safe and well tolerated.⁷

83 AML in older patients is associated with a dismal prognosis. With conventional intensive
84 chemotherapy, complete remission (CR) rates are comprised between 50% and 70% and the
85 relapse rate is high after remission, which results in median leukemia-free survival (LFS) of
86 about 12 months, median overall survival (OS) of 9 months and only 5-10% of patients are
87 long-term survivors.⁸⁻¹² There is thus a need to develop effective maintenance strategies, and
88 immunotherapies targeting NK cell represent attractive approaches.

89
90 In our previous phase I study of lirilumab⁷, we observed that different pharmacodynamic
91 profiles were associated with lirilumab dose: a transient saturation with the lowest dose
92 versus a sustained full saturation with higher doses (0.015mg/kg versus 0.3mg/kg and above
93 in that study). Evidence has highlighted the importance of KIR receptors in NK cell
94 maturation and education^{13,14} and suggests that, in the clinic, transient KIR blockade might
95 allow both the optimal activation of NK cells and the education of new NK cells towards the
96 end of each treatment cycle when occupancy is reduced.

97 In order to evaluate the clinical efficacy of lirilumab and to determine the optimal dose-
98 schedule, we designed a 3-arm phase II placebo-controlled study which compared the LFS of
99 elderly patients in first CR of AML treated with two dose-schedules of lirilumab or placebo.
100 A subset participated to a correlative study allowing for the double-blinded evaluation of the

101 functional and phenotypic changes induced by the 2 treatment arms compared to the control
102 group. The endpoints of the study were not met, and excess in early relapse led to early
103 termination of the study. Extensive analysis of the immune cell fate following KIR blockade
104 provides key elements to elucidate the potential mechanisms that led to this unexpected
105 excess of relapse despite inhibition of a major immune checkpoint.

106

107

108

109 **PATIENTS AND METHODS**

110 *Study design and treatment*

111 This is a prospective multicenter double-blinded phase II trial comparing two dose-schedules
112 of Lirilumab to a placebo control administered in the maintenance therapy of elderly patients
113 with AML in first CR following intensive chemotherapy. The study was conducted in 41
114 centers of the French ALFA and FILO cooperative groups.

115 Patients were randomized to one of the two treatment arms or placebo in a 1:1:1 ratio, with
116 minimization performed according to center, type of AML (primary versus secondary),
117 number of consolidation cycles (one versus two), and cytogenetics (high versus intermediate
118 risk). Lirilumab was administered at 0.1mg/kg every 12 weeks (arm A) or at 1mg/kg every 4
119 weeks (arm B) as a 1-hour IV infusion. Placebo (normal saline) was to be administered every
120 4 weeks as a 1-hour IV infusion in the placebo arm (arm C) and on weeks with no active
121 treatment in arm C, to ensure blinding. Patients were scheduled to receive 28-day cycles for
122 up to 24 months in the absence of intolerance or disease relapse. The study scheme is depicted
123 in Fig. 1. Lirilumab was provided by Innate Pharma (Marseille, France) as 5 mL vials
124 containing 10 mg/mL of lirilumab containing solution.

125 Study was approved by a national ethics committee (CPPRB) and registered at clinical
126 trial.gov (NCT01687387).

127

128 *Patients*

129 Main study eligibility criteria were: patients with de novo or secondary AML defined
130 according to World Health Organization 2008 criteria⁸, in first CR or CRi (according to the
131 revised recommendations of the International Working Group¹⁵) achieved after one or two
132 conventional induction chemotherapy and who had received one or two consolidation cycles.
133 Two different anthracycline-cytarabine containing induction and consolidation regimens
134 described in the Supplementary data section had been used as recommended by each

135 cooperative group. Induction chemotherapy had to have been administered within 6 months
136 before randomization and consolidation within 3 months following CR. Patient had to be non-
137 eligible for an allogeneic hematopoietic stem cell transplantation (allo-HSCT), to be aged of
138 60 to 80 years, to have an Eastern Cooperative Oncology Group (ECOG) performance status
139 of 0 or 1; to have adequate renal and hepatic function. Patients with a history of auto-immune
140 disease, patients on steroids were not eligible. All patients gave written informed consent
141 prior to inclusion in the study.

142

143 *Efficacy and safety assessments*

144 Safety was to be assessed, using Common Terminology Criteria for Adverse Events (CTCAE)
145 version 4.03. A safety analysis was performed every 6 months for safety assessment by the
146 DSMB. The primary efficacy variable for this trial was LFS, defined as the time elapsed
147 between randomization and the occurrence of disease relapse or death from any cause.
148 Secondary efficacy variables were the time to relapse (TTR), OS. TTR was defined as the
149 time elapsed between randomization and the occurrence of disease relapse; OS was the time
150 between randomization and death from any cause. Patients who had not progressed or died by
151 the time of the final analyses, were censored as of the date of last contact for calculation of
152 LFS, OS and TTR. Assessment of disease relapse was performed every 4 weeks during the
153 treatment and during follow-up periods. Relapse was defined according to IWG criteria.¹⁵

154

155 *Statistical analysis*

156 The planned sample size for the study comprised 150 patients (i.e., 50 patients were to be
157 randomized to each treatment arm). This sample size was estimated in order to demonstrate a
158 hazard ratio (HR) for LFS of 0.6 in favor of maintenance therapy with an 80% power for a
159 one-sided log-rank test at an overall alpha level of 5%. The final sample size consisted of 169
160 screened patients, 153 randomized patients, and 152 treated patients. All efficacy analyses
161 were performed using data from the Intention-to-treat (ITT) Population, which consisted of all
162 subjects who received at least one dose of study medication. The Safety Population used for
163 the safety analyses consisted of all patients who received at least one dose of lirilumab.

164 Following a DSMB meeting held on 10 March 2015, a unanimous recommendation was made
165 to stop further treatment for ongoing patients treated with lirilumab 1mg/kg due to an
166 apparent excess of early relapses compared with the two other groups. It was decided to keep
167 the same assumptions regarding the number of LFS events to be observed in these two

168 groups, i.e. 69 LFS events. Consequently, the primary efficacy analysis was performed on
169 these two groups, with the alpha level decreased to 2.5% and the power to 55%.

170 LFS was analyzed using the log-rank test stratified by the following stratification factors, as
171 recorded in the randomization file: primary versus secondary AML, and cytogenetics (high
172 versus intermediate risk). The stratification factor “number of consolidation cycles (1 versus
173 2)” was not used in the log-rank test because there were too few patients in some
174 combinations of strata and the log-rank test failed in this situation.

175

176 *Mass cytometry*

177 PBMC were collected at C1D1H0, C1D8, C4D1, C7D1 and end of study (EOS), and
178 cryopreserved in 10% DMSO. Forty-three patients participated to this correlative study (12 in
179 arm 0.1mg/kg, 16 in arm 1.0mg/kg and 15 in the control arm. A total of 141 samples were
180 analyzed among which 39 were collected at C1D1H0, 35 at C1D8, 26 at C4D1, 18 at C7D1,
181 and 23 at EOS. PBMCs were processed as previously described.^{5,16} The detailed protocol is
182 provided in appendix. Lymphocytes were exported for further analysis using opt-SNE¹⁷.
183 Lirilumab-bound cells were identified using a metal-conjugated anti-IgG4 antibody.

184

185

186

187 **RESULTS**

188 **Patient characteristics**

189 Between November 2012 and July 2014, 169 patients were screened, 153 were randomized,
190 and 152 were treated (Table 1). One patient was not treated in the lirilumab 0.1mg/kg arm,
191 due to consent withdrawal before treatment initiation. The final numbers of patients were 50
192 in the lirilumab 0.1mg/kg arm, 51 in the lirilumab 1mg/kg arm, and 51 in the placebo arm
193 (Fig. 1A). No significant imbalances were seen across treatment arms. Median age was 70
194 years. One fourth of patients had a favorable European LeukemiaNet (ELN) 2010 genetic
195 subtype of AML. The median time since AML diagnosis was 4.8 month and 81% of patients
196 had received two consolidation cycles prior to inclusion.

197

198 **Treatment**

199 Following a Data and Safety Monitoring Board (DSMB) recommendation on 10 March 2015,
200 the decision was made to stop further treatment for ongoing patients treated with lirilumab
201 1mg/kg due to an apparent excess of early relapses compared with the two other groups. At

202 that time, recruitment had already been completed. As a result, exposure was greater in the
203 lirilumab 0.1mg/kg arm (median number of cycles of 16) and in the placebo arm (median
204 number of cycles of 11) as compared to the lirilumab 1mg/kg arm (median number of cycles
205 of 8).

206 Relapse (62.7%) was the main reason for discontinuation (52.9% from the 0.1mg/kg arm,
207 72.5% from the 1mg/kg arm, and 62.7% from the placebo arm), followed by adverse events
208 (AEs) (10.5%), withdrawal of consent, investigator's decision, and sponsor's decision (1.3%
209 each) (Fig. S1).

210

211 **Efficacy results**

212 Efficacy analysis concerned only the comparison between lirilumab 0.1mg/kg versus placebo
213 (Fig. 1). The study did not meet its primary endpoint, as no significant difference between
214 lirilumab 0.1mg/kg and placebo was seen (stratified LFS Hazard ratio (HR): 0.98 (95%
215 confidence interval [CI], 0.61 to 1.56, $p=0.936$). The median LFS were 17.6, 6.7 and 13.9
216 months in the 0.1mg/kg arm, 1mg/kg arm and placebo arm, respectively. Regarding the
217 comparison between lirilumab 1mg/kg and placebo, no statistically significant difference was
218 observed, but LFS in the lirilumab 1mg/kg arm was inferior to that in the placebo arm
219 (median LFS of 6.7 months, HR 0.95; 95% CI, 0.59 to 1.53; $p=0.177$) (Fig. 1B).

220 With regard to secondary efficacy endpoints, no significant differences were found in any of
221 the comparisons which TTR times, median OS (31.3, 20.2 and 41.6 months in the 0.1mg/kg
222 arm, 1mg/kg arm and placebo arm, respectively, $p=0.602$ and 0.058) (Fig. 1C).

223 No prognostic factor for LFS for the comparison between lirilumab 0.1mg/kg and placebo
224 was seen. For the comparison of lirilumab 1mg/kg with placebo, the type of induction therapy
225 (idarubicin vs daunorubicin) and the number of platelets at the time of inclusion (<100 vs
226 $\geq 100 \times 10^9/L$) were identified in the Cox model as independent prognostic factors for LFS
227 (HR=1.35 and 4.14, respectively). Results are summarized as Forest Plots displayed in Fig.
228 S2A and S2B.

229 As previously mentioned, an excess in early relapse was observed and justified early
230 termination of treatment in the 1mg/kg arm. Although LFS was not statistically different
231 between arms, curves clearly show an early drop in LFS in this arm as compared to the 2
232 others.

233

234 **Safety**

235 Overall, 91.4% of patients had at least one treatment-emergent AE. The event rates (i.e. the
236 number of patients with AEs divided by the total drug exposure in months), was lower in the
237 lirilumab 0.1mg/kg arm than in the lirilumab 1mg/kg and the placebo arms. The most frequent
238 AEs are presented in Table 2. Infusion-related reactions were the most frequent, did not reach
239 a grade 4, while grade 3 reactions frequency was nearly identical in the three arms.
240 No significant hematological toxicity was seen in the 3 arms. Eighteen malignant tumors were
241 reported in 14 patients. 75% of patients were in the lirilumab 0.1mg/kg arm. There were 3
242 basal-cell carcinoma, and the other six neoplasms had each a maximum of one case. In the
243 other two arms combined, there were 3 myeloid malignancies, 6 solid tumors (including 2
244 basal cell carcinomas).
245 A total of 81 deaths were reported during the study: 26 in the lirilumab 0.1mg/kg arm, 32 in
246 the lirilumab 1mg/kg arm, and 23 in the placebo arm. Nearly 85% of such deaths were
247 attributed to disease progression across the three arms.

248

249 **Pharmacokinetics and pharmacodynamics**

250 PK-PD sampling was performed for the first 60 randomized patients. Intermittent full KIR
251 occupancy was observed with the dose of 0.1mg/kg every 3 months, with full KIR occupancy
252 lasting 7 days to 1 month for the majority of the patients. Long-term full KIR occupancy was
253 observed at the dose of 1mg/kg every 4 weeks (Fig. S3).

254

255 **Immune modifications during treatment**

256 Lirilumab was not immunogenic with 15 patients presenting Human Anti-Human Antibodies,
257 all with low titers. Of note, 9 out of the 15 positive patients tested positive at baseline and
258 5/15 patients were in the placebo arm (data not shown). Lirilumab-induced immune
259 modifications were then extensively analyzed by mass cytometry. For these experiments, we
260 used a metal-conjugated anti-IgG4 antibody in order to specifically identify lirilumab-bound
261 immune cells (Fig. 2A). As expected, based on prior *in vitro* studies¹⁸, lirilumab bound KIR-
262 expressing immune populations, including NK cells, V γ 9V δ 2⁺ γ δ T cells, CD8⁺ T cells, and to
263 a lesser extent CD4⁺ T cells (Fig. 2B-C). Eight days after lirilumab injection, 26.0% and
264 25.8% of NK cells had bound lirilumab in the lirilumab 0.1 and lirilumab 1.0 arms,
265 respectively (Fig. 2C). The frequency of lirilumab-bound V γ 9V δ 2⁺ γ δ T cells was 12.3% and
266 8.2% in the lirilumab 0.1 and lirilumab 1.0 arms, respectively. The mean frequency of
267 lirilumab-bound cells was below 6% for CD8⁺ T cells, and below 1% for CD4⁺ T cells in both
268 arms. The frequency of lirilumab-bound immune cells was significantly decreased by C4D1

269 in the lirilumab 0.1 arm, while maintained in the lirilumab 1.0 arm until the end of study (Fig.
270 2C).

271

272 The impact of lirilumab binding on NK cells was further characterized using dimensionality
273 reduction analysis. Since one of the main hypotheses retained to explain the lack of clinical
274 benefit of anti-KIR therapy in multiple myeloma was the potential interference with NK cell
275 education and development^{19,20}, we first focused on NK cell maturation profiles. Lirilumab
276 did not induce any phenotypical shift, even after prolonged administration, except a slight
277 decrease of CD56^{bright} NK cells at end of study (Fig. 3A and Fig. S4A). Besides, we observed
278 a transient decrease of the cluster of KIR⁺ NK cells in the lirilumab 0.1 arm, and a durable
279 decrease of this population in the lirilumab 1.0 arm (Fig. S4B). Analysis of absolute counts of
280 KIR⁺ NK cells in both arms at C1D8 evidenced a weak to drastic decrease in 17 out of 20
281 patients treated with lirilumab compared with baseline, while this decrease was weak and
282 limited to 3 out of 12 patients in the placebo arm (Fig. 3B), confirming prior observations in
283 multiple myeloma¹⁹. This decrease of KIR⁺ NK cells was concomitant with a transient
284 decrease at C1D8 of the anti-apoptotic protein Bcl-2 in the lirilumab 1.0 arm, a critical protein
285 NK cell survival.²¹ This decrease affected all the populations of NK cells, independently of
286 lirilumab binding (Fig. 3C), suggesting an indirect mechanism involved in the loss of Bcl-2
287 consecutive to KIR blockade. Although not significant, a similar trend was also observed in
288 the lirilumab 0.1 arm (Fig. 3C).

289

290 Lirilumab binding on CD8⁺ T cells did not induce any phenotypical shift (Fig. 4A), and did
291 not impact T cell maturation profiles (data not shown). Lirilumab spared naive (CD27⁺
292 CCR7⁺ CD45RA⁺ CD28⁺), central memory (CD27⁺ CCR7⁺ CD45RA⁻), and effector memory
293 (CD27⁻ CCR7⁻ CD45RA⁻) CD8⁺ T cells, and preferentially bound antigen-experienced CD8⁺
294 T cells with a terminally differentiated profile (CD27⁻ CCR7⁻ CD45RA⁺ CD28⁻). Most
295 lirilumab-bound CD8⁺ T cells also expressed CD56 and CD16, a phenotypic hallmark of T
296 cells with NK cell-like functions, and enhanced TCR-independent/CD16-dependent
297 degranulation potential.^{22,23} These cells also expressed the long-term immunological memory
298 marker CD57²⁴ (Fig. 4A). Upon lirilumab binding, we observed a decreased expression of the
299 activation marker CD69, a key regulator of tumor-specific CD8⁺ T cells differentiation.²⁵ This
300 decrease was significant in arm 1.0 at late time points (C7D1), specifically affected lirilumab-
301 bound CD8⁺ T cells, and spared lirilumab-free CD8⁺ T cells (Fig. 4B). We further analyzed
302 the effect of lirilumab binding at early time points on paired samples between C1D8 and

303 C4D1. Lirilumab was found to induce heterogeneous inter-individual responses after binding
304 to CD8⁺ T cells. In 4 out of 8 patients, lirilumab induced up-regulation of the key immune
305 checkpoints CTLA-4, PD-1, and BTLA, which was likely the consequence of a prior
306 activation, as evidenced by higher expression of CD25 (IL-2R), CD28, as well as the
307 inducible co-stimulatory receptors OX40 and 4-1BB (Fig. 4C). In these patients, we also
308 observed an increase of exhausted CD8⁺ T cells characterized by co-expression of PD-1 and
309 TIGIT, two co-inhibitory receptors increased upon T cell activation.²⁶

310 We next focused on vδ2⁺ γδT cells, a key population of anti-tumor cells with particular
311 relevance in the context of tumors with low mutational burden and high plasticity in MHC-I
312 expression such as AML.²⁷⁻³⁰ Lirilumab mainly bound vδ2⁺ γδT cells with a high cytotoxic
313 potential (CD8⁺ CD56⁺ CD57⁺ CD16⁺) (Fig. 5A). The number of anti-IgG4⁺ γδT cells was
314 insufficient in most patients from arm 0.1 and prevented performing reliable measurements in
315 this group. Upon administration, lirilumab induced a transient decrease of DNAM-1 at C7D1
316 in arm 1.0, a critical receptor involved in cytotoxicity (Fig. 5B). Besides, we observed a
317 decrease of absolute counts of anti-IgG4⁺ vδ2⁺ γδT cells between C1D8 et C4D1 in arm 1.0
318 (Fig. 5C). As for NK cells, depletion of lirilumab-bound vδ2⁺ γδT cells was associated with a
319 transient decrease of Bcl-2 at C1D8, affecting vδ2⁺ γδT cells independent of lirilumab binding
320 (Fig. 5B). The effect of lirilumab on Bcl-2 expression was not correlated with treatment
321 schedules, and some patients in arm 0.1 displayed marked decrease of Bcl-2 despite reduced
322 lirilumab dosing. We therefore performed a pooled analysis of both treatment arms according
323 to Bcl-2 expression among patients that relapsed before the end of study. Patients with LFS
324 above the median maintained a high frequency of Bcl-2⁺ vδ2⁺ γδT cells at C4D1, in contrast
325 to patients with LFS below the median (Fig. 5D). Consistently, the frequency of Bcl-2⁺ vδ2⁺
326 γδT cells was decreased in all patients with LFS<3mo, while the frequency of Bcl-2⁺ vδ2⁺
327 γδT cells was increased or stable in 8 out of 11 patients with LFS>3mo (Fig. 5E). In line,
328 patients with decreased Bcl-2 expression displayed shorter time to relapse than patients with
329 stable or increased Bcl-2 expression at C1D8 (Fig. 5E). The apparent recovery of Bcl-2 by
330 C4D1 (Fig. 5B) might therefore be artefactual and potentially biased by the fact that most
331 patients with loss of Bcl-2 between C1D0 and C1D8 display LFS<3mo. Taken together, these
332 results highlight a potential link between loss of Bcl-2 in vδ2⁺ γδT cells consecutive to KIR
333 blockade and early relapse in patients treated with lirilumab.

334

335 **DISCUSSION**

336 The current randomized phase II trial failed to meet its primary objective of demonstrating the
337 efficacy of lirilumab given as maintenance therapy in elderly patients in first CR from AML.
338 The primary endpoint, LFS, did not differ significantly between either of the lirilumab arms
339 and placebo arm, and there were no statistically significant differences in the secondary
340 efficacy endpoints of TTR and OS. However, the lirilumab 0.1mg/kg arm was associated with
341 a non-significant trend toward a higher LFS as compared to the placebo arm (17.6 versus 13.9
342 months) while an inverse trend was seen in the lirilumab 1mg/kg arm. The latter was stopped
343 early upon a DSMB decision due to the observation of a high rate of early relapse, which
344 translated into a shorter median OS (p=0.058).

345 We were not able to identify confounding factors which may explain the differences between
346 the 2 lirilumab arms. These include clinical and biological classical AML prognostic factors
347 such as the number of induction courses to achieve a CR, cytogenetics, and ELN genetic risk
348 classification. However, important parameters such as the level of minimal residual disease at
349 inclusion could not be assessed. Doses of 0.1mg/kg of lirilumab were associated with full but
350 transient KIR saturation on NK cells while 1mg/kg dose every 4 weeks led to continuous
351 saturation. However, it must be noted that substantial inter-patient variability was observed
352 and that some patients in the low dose arm actually achieved continuous full KIR saturation.

353

354 In order to decipher the mechanism involved in the excess of early relapse observed, we
355 developed mass cytometry panels to track lirilumab-bound cells during the course of
356 treatment, and dissect its impact on immune cell fate. We evidenced a decrease of KIR⁺ NK
357 cell absolute counts following KIR blockade, confirming the results of the phase II trial
358 assessing lirilumab in multiple myeloma.¹⁹ One hypothesis retained to explain the lack of
359 clinical benefit of anti-KIR therapy in this setting was the potential interference with NK cell
360 maturation homeostasis²⁰, the latter being critical in AML as recently evidenced by our
361 group.⁵ We failed to evidence maturation defects following lirilumab administration. Rather,
362 we evidenced a decrease of Bcl-2, a downstream target of IL-15 signaling, involved in
363 mitochondrial apoptosis, autophagy and senescence.³¹⁻³³ The ability of lirilumab to target T
364 cells was notable, confirming prior pre-clinical observations.¹⁸ Lirilumab preferentially bound
365 antigen-experienced CD8⁺ T cells, leading to a transient decreased activation. The impact of
366 lirilumab on the $\gamma\delta$ 2⁺ $\gamma\delta$ T cell compartment was marked by a decreased expression of
367 DNAM-1 and Bcl-2, the latter being associated with a decrease of the absolute counts of KIR⁺
368 $\gamma\delta$ T cell, echoing previous work showing that inhibitory KIR (iKIR) expression on human T

369 cells is associated with higher levels of Bcl-2, and that blocking the iKIR-HLA interaction
370 significantly decreased the count of live T cells^{34,35}. Similar observations have also been
371 reported in the context of renal cell carcinoma: blocking the interaction of KIR/HLA-Cw4
372 resulted in the restoration of tumor-induced cell death following activation by interfering with
373 two proximal events of Fas signaling pathway, a sustained c-FLIP-L induction and a decrease
374 in caspase 8 activity.³⁶ In line, recent work showed that KIR/HLA interactions extend lifespan
375 of human CD8⁺ T cells.³⁷ Although no confirmation of such mechanisms has been reported in
376 $\gamma\delta$ T cells, we can speculate that similar mechanisms triggering cell death are engaged
377 following KIR blockade on these cells, the latter point requiring dedicated mechanistic
378 studies. Finally, this loss of Bcl-2 was associated with a drastic reduction of time to relapse.
379 Given the strong correlation between Bcl-2 expression by $\gamma\delta$ T cells, CD8⁺ T cells and NK
380 cells, we cannot exclude a cumulative negative effect of Bcl-2 down-regulation on these three
381 main anti-leukemic populations. However, these results extend the list of arguments in favor
382 of the central role of $\gamma\delta$ T cells in the control of leukemic blast proliferation.

383 In conclusion, this study failed to demonstrate that lirilumab can prolong CR duration. In
384 addition, we observed potentially deleterious effects on various immune effectors. These
385 effects - which have not been previously reported - suggest that combined inhibitory effects
386 may have resulted in the impairment of immune surveillance associated with an unexpected
387 high rate of early relapse in the group of patients exposed to prolonged full KIR blockade.
388 The results also confirm the importance of $\gamma\delta$ T cells in the control of AML cells opening new
389 avenues for future immunotherapeutic strategies.^{38,39}

390 Overall, this study underlies the need to closely monitor the consequences of therapeutic
391 monoclonal antibodies binding on immune populations that appear minor in absolute number,
392 especially when these cells play a key role in tumor clearance. It also warns against the
393 possibility that immune interventions be associated with narrow therapeutic windows.

394

395

396 **Competing interests**

397 P.A. is an employee and a shareholder of Innate Pharma. D.O. is the co-founder and a
398 shareholder of Imcheck therapeutics, Emergence therapeutics, and Alderaan Biotech.

399 **Author contribution statement**

400 N.V. and H.D. designed the research. N.V., H.D., P.A., A.S.C., A.T., N.D., and D.O. designed
401 the ancillary study. N.V. and A.S.C analyzed the data and drafted the article. N.V., C.R., L.G.,
402 B.L., C.E.B, C.P., J.P.L, S.L., E.R., E.R., X.T., Y.H., C.B., B.C., P.R., J.V.M, G.G., J.H.B.,
403 M.O.U., M.H., C.P., N.I., and H.D. recruited patients, conducted patient follow-up, and
404 collected clinical data. A.B.A., N.B. and M.S.R. designed the mass cytometry panels and
405 performed the mass cytometry experiments. All authors revised and approved the manuscript.

406
407 **REFERENCES**

- 408
409 1. Caligiuri, M. A. Human natural killer cells. *Blood* **112**, 461–469 (2008).
410 2. Bryceson, Y. T., March, M. E., Ljunggren, H.-G. & Long, E. O. Synergy among receptors on resting NK
411 cells for the activation of natural cytotoxicity and cytokine secretion. *Blood* **107**, 159–166 (2006).
412 3. Caligiuri, M. A., Velardi, A., Scheinberg, D. A. & Borrello, I. M. Immunotherapeutic approaches for
413 hematologic malignancies. *Hematology Am Soc Hematol Educ Program* 337–353 (2004)
414 doi:10.1182/asheducation-2004.1.337.
415 4. Fauriat, C. *et al.* Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during
416 leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. *Blood* **109**, 323–330
417 (2007).
418 5. Chretien, A.-S. *et al.* High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a
419 subgroup with adverse clinical outcome. *Proc. Natl. Acad. Sci. U.S.A.* **118**, e2020459118 (2021).
420 6. Vey, N. *et al.* A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. *Blood*
421 **120**, 4317–4323 (2012).
422 7. Vey, N. *et al.* A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody
423 KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies. *Oncotarget* **9**, 17675–17688
424 (2018).
425 8. Vardiman, J. W. *et al.* The 2008 revision of the World Health Organization (WHO) classification of myeloid
426 neoplasms and acute leukemia: rationale and important changes. *Blood* **114**, 937–51 (2009).
427 9. Brune, M. Improved leukemia-free survival after postconsolidation immunotherapy with histamine
428 dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. *Blood*
429 **108**, 88–96 (2006).
430 10. Gardin, C. *et al.* Postremission treatment of elderly patients with acute myeloid leukemia in first complete
431 remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia
432 French Association (ALFA) 9803 trial. *Blood* **109**, 5129–5135 (2007).
433 11. Büchner, T. *et al.* Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia:
434 A Study by the German Acute Myeloid Leukemia Cooperative Group. *JCO* **27**, 61–69 (2009).
435 12. Löwenberg, B. *et al.* Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or
436 more: results of a multicenter phase 3 study. *Blood* **115**, 2586–2591 (2010).
437 13. Anfossi, N. *et al.* Human NK cell education by inhibitory receptors for MHC class I. *Immunity* **25**, 331–42
438 (2006).
439 14. Fauriat, C. *et al.* Estimation of the size of the alloreactive NK cell repertoire: studies in individuals
440 homozygous for the group A KIR haplotype. *J Immunol* **181**, 6010–9 (2008).
441 15. Cheson, B. D. *et al.* Revised recommendations of the International Working Group for Diagnosis,
442 Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials
443 in Acute Myeloid Leukemia. *Journal of clinical oncology* □: *official journal of the American Society of*
444 *Clinical Oncology* **21**, 4642–9 (2003).
445 16. Ben Amara, A. *et al.* High-throughput mass cytometry staining for deep phenotyping of human natural killer
446 cells. *STAR Protoc* **3**, 101768 (2022).
447 17. Belkina, A. C. *et al.* Automated optimized parameters for T-distributed stochastic neighbor embedding
448 improve visualization and analysis of large datasets. *Nat Commun* **10**, 5415 (2019).
449 18. Romagné, F. *et al.* Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic
450 antibody that augments natural killer-mediated killing of tumor cells. *Blood* **114**, 2667–2677 (2009).
451 19. Carlsten, M. *et al.* Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces
452 Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma. *Clinical Cancer Research* **22**,
453 5211–5222 (2016).
454 20. Sanchez-Correa, B. *et al.* Modulation of NK cells with checkpoint inhibitors in the context of cancer
455 immunotherapy. *Cancer Immunol Immunother* **68**, 861–870 (2019).

- 456 21. Malamut, G. *et al.* IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a
457 potential new target in celiac disease-associated inflammation and lymphomagenesis. *J Clin Invest* **120**,
458 2131–2143 (2010).
- 459 22. Björkström, N. K. *et al.* Elevated Numbers of Fc γ RIIIA+ (CD16+) Effector CD8 T Cells with NK Cell-Like
460 Function in Chronic Hepatitis C Virus Infection. *The Journal of Immunology* **181**, 4219–4228 (2008).
- 461 23. Georg, P. *et al.* Complement activation induces excessive T cell cytotoxicity in severe COVID-19. *Cell* **185**,
462 493–512.e25 (2022).
- 463 24. Ahmed, R. *et al.* CD57+ Memory T Cells Proliferate In Vivo. *Cell Rep* **33**, 108501 (2020).
- 464 25. Koyama-Nasu, R. *et al.* CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes.
465 *Cancer Immunol Res* **11**, 1085–1099 (2023).
- 466 26. Banta, K. L. *et al.* Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-
467 blockade to optimize anti-tumor CD8+ T cell responses. *Immunity* **55**, 512–526.e9 (2022).
- 468 27. Mensurado, S., Blanco-Domínguez, R. & Silva-Santos, B. The emerging roles of $\gamma\delta$ T cells in cancer
469 immunotherapy. *Nat Rev Clin Oncol* **20**, 178–191 (2023).
- 470 28. Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. *Science* **348**, 69–74 (2015).
- 471 29. Christopher, M. J. *et al.* Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. *N Engl J*
472 *Med* **379**, 2330–2341 (2018).
- 473 30. Toffalori, C. *et al.* Immune signature drives leukemia escape and relapse after hematopoietic cell
474 transplantation. *Nat Med* **25**, 603–611 (2019).
- 475 31. Chong, S. J. F. *et al.* Noncanonical Cell Fate Regulation by Bcl-2 Proteins. *Trends Cell Biol* **30**, 537–555
476 (2020).
- 477 32. Czabotar, P. E. & Garcia-Saez, A. J. Mechanisms of BCL-2 family proteins in mitochondrial apoptosis. *Nat*
478 *Rev Mol Cell Biol* **24**, 732–748 (2023).
- 479 33. Ma, S., Caligiuri, M. A. & Yu, J. Harnessing IL-15 signaling to potentiate NK cell-mediated cancer
480 immunotherapy. *Trends Immunol* **43**, 833–847 (2022).
- 481 34. Boelen, L. *et al.* Inhibitory killer cell immunoglobulin-like receptors strengthen CD8⁺ T cell-mediated
482 control of HIV-1, HCV, and HTLV-1. *Sci. Immunol.* **3**, eaao2892 (2018).
- 483 35. Young, N. T., Uhrberg, M., Phillips, J. H., Lanier, L. L. & Parham, P. Differential Expression of Leukocyte
484 Receptor Complex-Encoded Ig-Like Receptors Correlates with the Transition from Effector to Memory CTL.
485 *The Journal of Immunology* **166**, 3933–3941 (2001).
- 486 36. Gati, A. *et al.* CD158 receptor controls cytotoxic T-lymphocyte susceptibility to tumor-mediated activation-
487 induced cell death by interfering with Fas signaling. *Cancer Res* **63**, 7475–7482 (2003).
- 488 37. Zhang, Y. *et al.* KIR-HLA interactions extend human CD8+ T cell lifespan in vivo. *Journal of Clinical*
489 *Investigation* **133**, e169496 (2023).
- 490 38. Cano, C. E. *et al.* BTN2A1, an immune checkpoint targeting V γ 9V δ 2 T cell cytotoxicity against malignant
491 cells. *Cell Rep* **36**, 109359 (2021).
- 492 39. De Gassart, A. *et al.* Development of ICT01, a first-in-class, anti-BTN3A antibody for activating V γ 9V δ 2 T
493 cell-mediated antitumor immune response. *Sci Transl Med* **13**, eabj0835 (2021).
- 494
495
496

497 **Table 1:** Patient characteristics

	1 mg/kg Q4W	0.1 mg/kg Q12W	Placebo Q4W
	N=51 (100%)	N=50 (100%)	N=51 (100%)
Median age years (range)	70 (60-80)	70 (60-80)	69 (60-77)
Sex (Female)	28 (55%)	16 (32%)	17 (33%)
ECOG			
0	28 (55%)	27 (54%)	35 (69%)
1	23 (45%)	23 (46%)	16 (31%)
Secondary AML	6 (12%)	9 (18%)	7 (14%)
ELN 2010 risk category			
- Favorable	15 (29%)	12 (24%)	12 (24%)
- Intermediate-1 / 2	25 (49%)	27 (54%)	26 (51%)
- Adverse	5 (10%)	6 (12%)	5 (10%)
Prior therapy			
- Induction (1 cycle / 2 cycles)	50 (98%) / 1 (2%)	50 (100%) / 0	48 (94%) / 3 (6%)
- Consolidation (1 cycle / 2 cycles)	10 (20%) / 41 (80%)	9 (18%) / 41 (82%)	10 (20%) / 41 (80%)
- Consolidation (1+5 / IDAC)	28 (55%) / 23 (45%)	20 (40%) / 29 (58%)	32 (63%) / 19 (37%)
Median months since CR (range)	3.0 (1.1-5.0)	3.3 (1.3-5.5)	3.3 (2.0-5.9)

498

499

500 **Table 2:** Adverse events occurring in >10% of patients

501

	Lirilumab		Lirilumab		Placebo Q4W		Total	
	1 mg/kg	Q4W	0.1 mg/kg	Q12W	Placebo Q4W		Total	
	(N =51)		(N = 50)		(N=51)		(N = 152)	
	All grades	Grade 3 or 4	All grades	Grade 3 or 4	All grades	Grade 3 or 4	All grades	Grade 3 or 4
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
Any AE	48 (84)	15(29)	49 (98)	28 (56)	47 (92)	14 (29)	139 (91)	58 (38)
Asthenia	14 (28)	1 (2)	14 (28)	1 (2)	14 (28)	0	42 (28)	2 (1)
Bronchitis	6 (12)	0	17 (34)	0	14 (28)	0	37 (24)	0
Pruritus	8 (16)	0	10 (20)	0	7 (14)	0	25 (16)	0
Thrombocytopenia	9 (18)	3 (6)	7 (14)	4 (8)	3 (6)	2 (4)	19 (13)	9 (6)
Diarrhea	8 (16)	1 (2)	6 (12)	0	2 (4)	0	16 (11)	1 (1)
Back pain	3 (6)	0	6 (12)	0	7 (14)	0	16 (11)	0
Arthralgia	4 (8)	1 (2)	6 (12)	0	5 (10)	0	15 (10)	1 (1)
Headache	8 (16)	0	4 (8)	0	3 (10)	0	15 (10)	0
Pyrexia	6 (12)	0	4 (8)	0	5 (10)	0	15 (10)	0

502

503

504

505 **Figure legends**

506

507 **Figure 1: Clinical outcome in patients treated with lirilumab 1.0 mg/kg, lirilumab 0.1**
508 **mg/kg or placebo.** A: Study design. B: Primary endpoint: Leukemia-Free Survival. C:
509 Secondary endpoint : Overall Survival.

510

511 **Figure 2: Distribution of lirilumab binding on immune populations.** PBMC from patients
512 in arm 0.1 mg/kg (N=12), arm 1.0 mg/kg (N=16) and control arm (N=15) were collected at
513 C1D1H0, C1D8, C4D1, C7D1 and EOS and phenotyped by mass cytometry. A: Lirilumab-
514 bound cells were identified using metal-conjugated an α -IgG4 antibody. B: Consensus files
515 were generated using fixed number of α IgG4+ cells from each .fcs file, and projected on a t-
516 SNE map. C: Frequency of α IgG4+ cells by treatment arm and by time point of blood
517 collection among CD4+ T cells, CD8+ T cells, $V\delta 2+$ $\gamma\delta$ T cells, and NK cells. Data were
518 analyzed using a Kruskal-Wallis test followed by a Dunn's post test. * $P < 0.05$; ** $P < 0.01$;
519 *** $P < 0.001$; ns, nonsignificant. C1D1H0: cycle 1 day 1 hour 0; C1D8: cycle 1 day 8; C4D1:
520 cycle 4 day 1; C7D1: cycle 7 day 1; EOS: end of study.

521

522 **Figure 3 : Impact of lirilumab on NK cells.** A: Total peripheral NK cells were manually
523 pre-gated and exported for t-SNE analysis. Consensus files of α IgG4+ NK cells were
524 generated with fixed number of cells for each treatment arm at each time point in order to
525 obtain a representative and balanced view of all patient groups. Consensus files were then
526 projected on t-SNE plots of total NK cells. B: Variations of absolute counts of KIR+ NK cells
527 between baseline and C1D8. C: Bcl-2 expression by treatment arm and by time point of blood
528 collection. C1D1H0 were pre-gated on KIR+ NK cells. C1D8 to EOS were pre-gated on
529 KIR+ cells for placebo arm. C1D8 to EOS were pre-gated on α IgG4+ NK cells for arms A
530 and B. Paired samples were analyzed using a Wilcoxon matched-pairs signed rank test. For
531 multiple comparisons, data were analyzed using a Kruskal-Wallis test followed by a Dunn's
532 post test, and presented as interquartile ranges, median, and whiskers from minimum to
533 maximum. * $P < 0.05$; ** $P < 0.01$; ns, nonsignificant. C1D1H0: cycle 1 day 1 hour 0; C1D8:
534 cycle 1 day 8; C4D1: cycle 4 day 1; C7D1: cycle 7 day 1; EOS: end of study; PCB: placebo.

535

536 **Figure 4: Impact of lirilumab on CD8+ T cells.** A: Total peripheral CD8+ T cells were
537 manually pre-gated and exported for t-SNE analysis. Consensus files of α IgG4+ CD8+ T cells
538 were generated with fixed number cells for each treatment arm at each time point. Consensus

539 files were then projected on t-SNE plots of total CD8+ T cells. B: CD69 expression by
540 treatment arm and by time point of blood collection. C: Variations of T cell triggering
541 receptors, immune checkpoints and activation markers expression between C1D8 and C4D1.
542 Paired samples from patients included in 1.0 arm were analyzed using hierarchical clustering.
543 For multiple comparisons, data were analyzed using a Kruskal-Wallis test followed by a
544 Dunn's post test, and presented as interquartile ranges, median, and whiskers from minimum
545 to maximum. * $P < 0.05$; ** $P < 0.01$; ns, nonsignificant. C1D1H0: cycle 1 day 1 hour 0;
546 C1D8: cycle 1 day 8; C4D1: cycle 4 day 1; C7D1: cycle 7 day 1; EOS: end of study.

547


548 **Figure 5 : Impact of lirilumab on $v\delta 2+$ $\gamma\delta T$ cells.** A: Total peripheral $v\delta 2+$ $\gamma\delta T$ cells were
549 manually pre-gated and exported for t-SNE analysis. Consensus files of $\alpha IgG4+$ $v\delta 2+$ $\gamma\delta T$
550 cells were generated with fixed number cells for each treatment arm at each time point.
551 Consensus files were then projected on t-SNE plots of total $v\delta 2+$ $\gamma\delta T$ cells. B: DNAM-1 and
552 Bcl-2 expression by treatment arm and by time point of blood collection. C1D1H0 were pre-
553 gated on KIR+ NK cells. C1D8 to EOS were pre-gated on KIR+ cells for placebo arm. C1D8
554 to EOS were pre-gated on $\alpha IgG4+$ NK cells for arms A and B. C: variations of absolute
555 counts of $\alpha IgG4+$ $v\delta 2+$ $\gamma\delta T$ cells during the cours of treatment. D: Bcl-2 expression at C1D8
556 according to LFS. E: Variations of Bcl-2 expression between C1D1H0 and C1D8 according
557 to LFS (upper and middle panels). Time to relapse according to Bcl-2 variations between
558 C1D1H0 and C1D8 (lower panel). For multiple comparisons, data were analyzed using a
559 Kruskal-Wallis test followed by a Dunn's post test, and presented as interquartile ranges,
560 median, and whiskers from minimum to maximum. Paired samples were analyzed using a
561 Wilcoxon matched-pairs signed rank test. Comparison between two groups were performed
562 using a Mann-Whitney U test. * $P < 0.05$; ** $P < 0.01$; ns, nonsignificant. C1D1H0: cycle 1
563 day 1 hour 0; C1D8: cycle 1 day 8; C4D1: cycle 4 day 1; C7D1: cycle 7 day 1; EOS: end of
564 study; LFS: leukemia-free survival; PCB: placebo.

565


566

567

A



B



C




Figure 1: Clinical outcome in patients treated with lirilumab 1.0 mg/kg, lirilumab 0.1 mg/kg or placebo. A: Study design. B: Primary endpoint: Leukemia-Free Survival. C: Secondary endpoint : Overall Survival.

